Objective To study the protective effect of Ornithine Aspartate on chemotherapy of gastrointestinal tumors with HBV Infection.Methods 98 cases of gastrointestinal tumors with HBV were divided randomly into two groups, 47 cases in observation group were treated with Ornithine Aspartate (10 g per day venous instillation) 3 days before and during the FOLFOX chemotherapy, and 51 cases in control group were treated with FOLFOX chemotherapy alone.HBV DNA load was detected with PCR before and during chemotherapy.Liver function, blood routine, weight, T lymphocyte subsets and KPS score were also detected before and during chemotherapy.Results The increment in total bilirubin, ALT and AST greater than 2 times in control group was higher than that in observation group after treatment, and weight loss and decline in KPS score in control group was higher than that in observation group;Bone marrow suppression and T lymphocyte subsets showed no significant difference between the two groups.The number of HBV DNA copy was increased after treatment in both the groups, but there was no significant difference between the two groups.Conclusion Ornithine Aspartate was effective in the prevention and treatment of the liver function damage caused by chemotheraphy in patients with gastrointestinal tumors with HBV.It also improved weight loss and physical activity and enhanced the tolerance to therapy in patients with FOLFOX chemotherapy.
DownLoad: